Physician profile
Gary Maassen
NPI 1831170968
$3,297.76
in general payments reported to CMS, 2019-2025
30 companies · $14.30 in 2025
The $14.30 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $241 · 2021: $615 · 2022: $718 · 2023: $890 · 2024: $16.44 · 2025: $14.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $451.67 | 2019-2023 | |
| Novo Nordisk INC | $388.62 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $248.59 | 2019-2023 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $231.94 | 2019-2023 | |
| Glaxosmithkline, LLC. | $214.23 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.13 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $167.70 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $142.00 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $137.32 | 2019-2022 | |
| Lilly USA, LLC | $134.96 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.92 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $115.54 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Astellas Pharma US INC | $112.38 | 2019-2023 | Veozah |
| Abbvie INC. | $111.29 | 2019-2023 | |
| Amgen INC. | $105.47 | 2021-2023 | Otezla, Repatha, Prolia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78.14 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.68 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $38.81 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $34.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $33.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.79 | 2023 | Gvoke Hypopen |
| Endo Pharmaceuticals INC. | $23.50 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $23.04 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $22.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.75 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.75 | 2022 | |
| Circassia INC. | $17.66 | 2019 | |
| Sumitomo Pharma America, INC. | $16.44 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $16.27 | 2022 | |
| Dexcom, INC. | $14.31 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Maassen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.